<DOC>
	<DOC>NCT02289755</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of ALLN-177 to reduce urinary oxalate excretion in patients with recurring kidney stones and enteric or idiopathic hyperoxaluria.</brief_summary>
	<brief_title>Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria</brief_title>
	<detailed_description>A multi-center, open-label, single arm study to evaluate the safety and the effect of ALLN-177 to reduce urinary oxalate excretion in recurrent kidney stone formers with associated hyperoxaluria. The study design includes a screening period to confirm eligibility, followed by a 3-day baseline period, 4-day open label treatment period with ALLN-177 and 4-day follow up period.</detailed_description>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<criteria>Able to provide informed consent Able to comply with study procedures History of enteric or idiopathic hyperoxaluria and at least one calcium oxalate kidney stone Hyperoxaluria &gt;36mg of oxalate/24hr May be taking drugs for the prevention of stone disease as long as there have been no changes in these medications for at least 3 months Uric acid â‰¥1.5g/24hr Estimated glomerular filtration rate of &lt; 60 mL/min Positive results from drug urine screen Requires daily vitamin C (defined as &gt;10 days of &gt;300 mg/day) Diagnosis of hypercalcemia or hypothyroidism Obstructive uropathy, chronic urosepsis, renal failure, renal tubular acidosis, primary hyperparathyroidism, primary hyperoxaluria, pure uric acid and cystine stones, and/or medullary sponge kidney. Autoimmune disorder requiring high dose steroids or other immunosuppressant drugs. Subjects who are pregnant. Women of childbearing potential must have a negative pregnancy test prior to enrollment and must practice approved methods of birth control during the trial History of cancer diagnosis except for within the past 5 years excluding dermal squamous and/or basal cell carcinoma or cervical carcinoma in situ. Taken investigational compound within 30 days prior to the first day of the study Treatment with cholestyramine Average daily dietary intake of &lt;75 mg oxalate per day calculated from diet recalls</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Urine Oxalate</keyword>
	<keyword>Nephrolithiasis</keyword>
	<keyword>Kidney Stones</keyword>
	<keyword>Hyperoxaluria</keyword>
	<keyword>Enteric Hyperoxaluria</keyword>
	<keyword>Idiopathic Hyperoxaluria</keyword>
	<keyword>Urological Diseases</keyword>
	<keyword>Kidney Diseases</keyword>
</DOC>